Literature DB >> 22310686

A delicate balance: tweaking IL-2 immunotherapy.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22310686     DOI： 10.1038/nm0212-208

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

Review 1.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

Authors:  Thomas R Malek; Iris Castro
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

Review 2.  Regulatory T cells and immune tolerance.

Authors:  Shimon Sakaguchi; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono
Journal:  Cell       Date:  2008-05-30       Impact factor: 41.582

3.  Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.

Authors:  Ho-Jin Shin; Jeanette Baker; Dennis B Leveson-Gower; Aaron T Smith; Emanuela I Sega; Robert S Negrin
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

Review 4.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

Authors:  S A Rosenberg; M T Lotze
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

5.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

Authors:  David Saadoun; Michelle Rosenzwajg; Florence Joly; Adrien Six; Fabrice Carrat; Vincent Thibault; Damien Sene; Patrice Cacoub; David Klatzmann
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

6.  Interleukin-2 and regulatory T cells in graft-versus-host disease.

Authors:  John Koreth; Ken-ichi Matsuoka; Haesook T Kim; Sean M McDonough; Bhavjot Bindra; Edwin P Alyea; Philippe Armand; Corey Cutler; Vincent T Ho; Nathaniel S Treister; Don C Bienfang; Sashank Prasad; Dmitrios Tzachanis; Robin M Joyce; David E Avigan; Joseph H Antin; Jerome Ritz; Robert J Soiffer
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

7.  Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.

Authors:  W Willenbacher; N Basara; I W Blau; A A Fauser; M G Kiehl
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

Review 8.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

9.  A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells.

Authors:  Aixin Yu; Linjian Zhu; Norman H Altman; Thomas R Malek
Journal:  Immunity       Date:  2009-01-29       Impact factor: 31.745

10.  In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression.

Authors:  Kylie E Webster; Stacey Walters; Rachel E Kohler; Tomas Mrkvan; Onur Boyman; Charles D Surh; Shane T Grey; Jonathan Sprent
Journal:  J Exp Med       Date:  2009-03-30       Impact factor: 14.307
View more
  7 in total

1.  Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.

Authors:  P Schlegel; T Feuchtinger; C Nitschke-Gérard; U J Eva Seidel; A-M Lang; C Kyzirakos; H-M Teltschik; M Ebinger; M Schumm; E Koscielniak; R Handgretinger; P Lang
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

2.  Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses.

Authors:  Thomas Höfer; Oleg Krichevsky; Grégoire Altan-Bonnet
Journal:  Front Immunol       Date:  2012-09-05       Impact factor: 7.561

3.  The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses.

Authors:  Brendon J Coventry; Martin L Ashdown
Journal:  Cancer Manag Res       Date:  2012-08-02       Impact factor: 3.989

4.  Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation.

Authors:  Brendon J Coventry; Martin L Ashdown
Journal:  Cancer Manag Res       Date:  2012-05-28       Impact factor: 3.989

Review 5.  The Immune System and Responses to Cancer: Coordinated Evolution.

Authors:  Brendon J Coventry; Martin Ashdown; Maciej Henneberg
Journal:  F1000Res       Date:  2015-08-12

6.  Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma.

Authors:  Akinori Masuda; Kyoko Arai; Daisaku Nishihara; Tomoya Mizuno; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Hideyuki Abe; Masahiro Yashi; Yoshitatsu Fukabori; Ken-Ichiro Yoshida; Takao Kamai
Journal:  Biomed Res Int       Date:  2014-06-25       Impact factor: 3.411

Review 7.  Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.

Authors:  Shan Gao; Dongjuan Yang; Yan Fang; Xiaojie Lin; Xuechao Jin; Qi Wang; Xiyan Wang; Liyuan Ke; Kai Shi
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.